Nah. Have to disagree with you here. They have bee

Nah. Have to disagree with you here. They have been together in some form or another for years - pre Nanoviricide - which immediately contracted with Kard. NNVC bought property from Theracorp Pharma in 2005 - K.Menon was on Theracour board and Theracour contracted with Kard. Anil Duwan was president and director of Theracour at the time and became president and director of NNVC also - holding both positions - both companies contracting Kard and Menon on board of Theracour and employed by NNVC, Ehlrich was Theracour CFO and then NNVC CFO and now major NNVC stockholder. NNVC was a share machine for the longest time, as many people here who were burned know. The activity circle revolves around Kard - the only nonpublic company involved here. And fwiw - Menon's son is listed as Kard founder in Nanoantibiotics 10k (please go to Edgar and read it from the source) - even though he was still a college student when company started. from the nanoabt registration statement p 31: "Mr. Rajah Menon. Mr. Menon has served as the Company’s President and as a Director since the Company’s inception on April 10, 2013. Mr. Menon attended Amherst College from 1996 -2000 where he received his Bachelor of Arts’ degrees in Economics and Law Jurisprudence and Social Thought. After graduation in 2002, and to 2004, Mr. Menon worked as an analyst for Loan Pricing Corporation, a subsidiary of Reuters. In 2002, Mr. Menon founded Kard Scientific, a preclinical contract research organization providing life science services to companie based near Boston, MA, and today he remains its principal shareholder. In the years 2004-2008, Mr. Menon was employed at Blackrock Financial Management as a Vice President within the Portfolio Analytics Group. >From 2008 – 2013, Mr. Menon was employed at Markit as a Product Manager within its Structured Finance group."

Blah. Too many circles. Red flags. As investors, we are wise to look at such things without emotion. Without labels of 'basher' if one finds something of concern in a company. I will no longer be heavy in this company. Once had lopsided position. No more. But I will continue to hold shares for Kevetrin - which is the real thing. Even if Kevetrin is not outstanding on its own - if it lacks toxicity and is well-tolerated, it has the potential to become a much used piggyback drug. Kevetrin is the positive story of this company. Leo creating so many legal business deductions for the same crowd is a reason to be cautious and not go overweight.